UCB, BE0003739530

UCB stock: BIMZELX peak-sales guidance reaches at least EUR 7 billion

Published on 11/18/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock outlined a broader growth plan at the Jefferies Global Healthcare Conference. Management highlighted BIMZELX, neurology and further deal capacity.

UCB broadens its growth outlook

  • Management presented BIMZELX as an anchor within a broader immunology and neurology portfolio.
  • The drug has shown superiority in four head-to-head trials across psoriasis and psoriatic arthritis.
  • Chief Executive Jean-Christophe Tellier said adoption has been slower than the clinical evidence would suggest.
  • UCB sees further acquisitions as a way to strengthen areas close to its existing expertise.
UCB, BE0003739530, Illustration mit AI erstellt.

UCB outlined a broader growth plan at the Jefferies Global Healthcare Conference on Tuesday, November 17, according to Investing.com. Chief Executive Jean-Christophe Tellier presented BIMZELX as the anchor of a portfolio that also includes neurology assets, new treatment platforms and potential external growth.

UCB stock traded at 287.75 euros on Lang & Schwarz at 11:32 CET on Wednesday, November 18.

BIMZELX remains the main growth anchor

Management said BIMZELX has shown superiority against standard care in four head-to-head trials covering psoriasis and psoriatic arthritis. Tellier described the comparative record as unprecedented and said about 150,000 patients are now receiving the drug.

The company said clinical performance has not yet translated into the market share gains it expected. Management pointed to established prescribing habits, rebate structures and step-edit rules as factors that can slow adoption. Psoriatic arthritis was highlighted as an additional opportunity because it affects about 30% of people with psoriasis.

UCB also identified hidradenitis suppurativa as an early commercial opportunity. The company said its studies were designed against standard care and that the condition remains underdiagnosed and undertreated. Management cited an average seven-year gap between symptom onset and diagnosis.

Portfolio expansion reaches neurology

The conference discussion extended beyond immunology. UCB said its neurology strategy is moving from symptom control toward disease modification, with RYSTIGGO and ZILBRYSQ supporting its myasthenia gravis franchise and FINTEPLA remaining part of its epilepsy portfolio.

Management also discussed acquisitions completed in 2024, including IMIDomics, Antengene, Neurona and Candid. The deals added capabilities in areas such as cell therapy and early-stage discovery while remaining close to UCB's existing scientific expertise. Tellier said the company has room to pursue additional transactions but is not under pressure to act quickly.

The longer-term strategy combines BIMZELX with bispecific and T-cell engager programmes in immunology. In neurology, UCB is pursuing disease-modifying approaches for severe forms of epilepsy. The company said BIMZELX patent protection extends to 2037, while four additional growth drivers have protection into the early 2030s.

Cash generation supports strategic flexibility

UCB said EVENITY continues to contribute cash flow and that disciplined profit-and-loss management gives it flexibility to invest in launches, manufacturing and business development. The company is building a mammalian manufacturing facility in the United States to improve supply security and geographic diversification.

For investors, the conference reinforced the tension between strong clinical differentiation and the slower pace of commercial adoption. The next phase of the story depends on whether BIMZELX can convert its comparative data into broader prescribing and whether the pipeline produces additional growth drivers.

Across the Belgian market, the Euro Stoxx 50 provides the relevant regional equity backdrop.

More news and analyses on UCB stock

UCB S.A. at a glance

  • Company: UCB S.A.
  • ISIN: BE0003739530
  • Sector: Healthcare
  • Industry: Biotechnology
  • Chief executive: Jean-Christophe Tellier
  • Lang & Schwarz quote: 287.75 euros at 11:32 CET on November 18, 2026
Disclaimer...
en | BE0003739530 | UCB | boerse | 70530498 | bgmi